Answers are grounded in this paper and cite their sources.
Denileukin diftitox at current dose schedule has limited activity in patients with previously treated NSCLC, manifested by disease control without impact on survival.
No takes yet. Share an insight, caveat, or question.
Gerena-Lewis et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: